The AMADEUS trial, a multicenter, randomized, open-label, assessor blind, non-inferiority study comparing the efficacy and safety of once-weekly subcutaneous idraparinux (SR34006) with adjusted-dose oral vitamin-K antagonists in the prevention of thromboembolic events in patients with atrial fibrillation.

Trial Profile

The AMADEUS trial, a multicenter, randomized, open-label, assessor blind, non-inferiority study comparing the efficacy and safety of once-weekly subcutaneous idraparinux (SR34006) with adjusted-dose oral vitamin-K antagonists in the prevention of thromboembolic events in patients with atrial fibrillation.

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Dec 2015

At a glance

  • Drugs Idraparinux sodium (Primary) ; Acenocoumarol; Warfarin
  • Indications Stroke; Thromboembolism
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms AMADEUS
  • Sponsors Sanofi
  • Most Recent Events

    • 01 Dec 2015 Post hoc analysis results (n=1588) from elderly patients with respect Body Mass Index published in the Stroke.
    • 28 Jan 2008 Results have been published in the Lancet.
    • 22 Oct 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top